| MDL | - |
|---|---|
| Molecular Weight | 394.40 |
| Molecular Formula | C20H19FN6O2 |
| SMILES | FC(C=C1)=CC(C=C2)=C1N=C2CN[C@H]3[C@@]4([H])[C@]3([H])CN(C5=NC=C(C(NO)=O)C=N5)C4 |
Nanatinostat (CHR-3996) is a potent, class I selective and orally active histone deacetylase (HDAC) inhibitor with an IC 50 of 8 nM [1] .
IC50:8 nM ( HDAC) [1]
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00697879 | Chroma Therapeutics |
Solid Tumor
|
February 2008 | Phase 1 |
| NCT05166577 | Viracta Therapeutics, Inc. |
Nasopharyngeal Carcinoma|EBV-Related Gastric Carcinoma|EBV-Related Leiomyosarcoma|EBV Related Carcinoma|EBV-Related Sarcoma
|
October 7, 2021 | Phase 1|Phase 2 |
| NCT05011058 | Viracta Therapeutics, Inc. |
Epstein-Barr Virus Associated Lymphoproliferative Disorder|EBV-Related PTLD|EBV Related Non-Hodgkin´s Lymphoma|Extranodal NK+T-cell Lymphoma|EBV-Positive DLBCL, Nos|EBV Associated Lymphoma|EBV-Related Hodgkin Lymphoma|EBV Related PTCL, Nos
|
May 28, 2021 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
DMSO : 33.33 mg/mL ( 84.51 mM ; Need ultrasonic)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.5355 mL | 12.6775 mL | 25.3550 mL |
| 5 mM | 0.5071 mL | 2.5355 mL | 5.0710 mL |
| 10 mM | 0.2535 mL | 1.2677 mL | 2.5355 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: 2.5 mg/mL (6.34 mM); Suspended solution; Need ultrasonic